Trial Profile

Recurrent Brain Metastasis Immune Effects and RespOnse to Laser Interstitial ThermotHerapy (LITT) and Pembrolizumab in Combination (TORCH)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 29 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications B-cell lymphoma; Brain metastases; Cervical cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Squamous cell cancer; Urogenital cancer
Focus Pharmacodynamics
Acronyms TORCH

Most Recent Events

20 Dec 2023 Status changed from active, no longer recruiting to discontinued.
16 Nov 2023 Status changed from recruiting to active, no longer recruiting.
16 Feb 2023 Planned End Date changed from 1 Oct 2025 to 1 Oct 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com